Rite Aid Posts December and Year-to-Date Sales

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Rite Aid Posts December and Year-to-Date Sales

© courtesy of RiteAid

Rite Aid Corp. (NYSE: RAD) is keeping its investors up to date with its most recent monthly sales report. The company reported its sales results for the month of December, as well as its year-to-date results.

For the four weeks ended on December 26, 2015, same-store sales decreased 0.1% over the same period from the previous year. December front-end same-store sales increased 0.8%. Pharmacy same-store sales, which included an approximate 207 basis points negative impact from new generic introductions, decreased 0.6%. Prescription count at comparable stores decreased 0.4% over the prior-year period.

In terms of the total drugstore sales, the company posted sales of $2.212 billion, compared to $2.212 billion for the same four-week period last year. Prescription sales accounted for 64.6% of drugstore sales, and third-party prescription sales represented 98.0% of pharmacy sales.

Looking at the 43-week period ended on December 26, 2015, same-store sales increased 1.7% over the prior-year period. Front-end same-store sales increased 0.4%, while pharmacy same-store sales increased 2.3%. Prescription count at comparable stores increased 0.5% over the prior-year period.
[ims_survey]
Total drugstore sales for the 43-week period, increased 1.6%, with sales of $22.118 billion, compared to $21.765 billion for the same period last year. Prescription sales represented 69.0% of total drugstore sales, and third-party prescription sales represented 97.8% of pharmacy sales.

The company operated 4,558 stores, compared to 4,570 stores in the same period from last year.

As 2015 is coming to a close, Rite Aid has outperformed the market, with the stock up 4.3% year to date.

Shares of Rite Aid were trading at $7.83 Thursday morning, with a consensus analyst price target of $9.05 and a 52-week trading range of $5.88 to $9.47.

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618